

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 2801-18

BOTTAZZI et al.

C# M#

Serial No. 09/555,473

Group Art Unit: 1644

Filed: May 31, 2000

Examiner: Jamroz

Date: November 2, 2001

Title: PHARMACEUTICAL COMPOSITIONS CONTAINING THE LONG PENTRAXIN  
PTX3Assistant Commissioner for Patents  
Washington, DC 20231

TECH CENTER 1600/2900

NOV 06 2001

RECEIVED

\$3

Sir:

**RESPONSE/AMENDMENT/LETTER**

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

**Fees are attached as calculated below:**

Total effective claims after amendment 0 minus highest number  
previously paid for 20 (at least 20) = 0 x \$ 18.00 \$ 0.00

Independent claims after amendment 0 minus highest number  
previously paid for 3 (at least 3) = 0 x \$ 84.00 \$ 0.00

If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper) \$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this  
paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months) \$ 0.00

Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00

☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00) \$ 0.00

☐ Please enter the previously unentered, filed

☐ Submission attached

**Subtotal** \$ 0.00

If "small entity," then enter half (1/2) of subtotal and subtract -\$ 0.00

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: 0.00

**TOTAL FEE ENCLOSED** \$ 0.00

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8<sup>th</sup> Floor  
Arlington, Virginia 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
BJS:

NIXON & VANDERHYE P.C.  
By Atty: B. J. Sadoff, Reg. No. 36,663

Signature: 

11/07/2001 BDUCKETT 00000001 141140 09555473

01 FC:102

84.00 CH



In re Patent Application of  
**BOTTAZZI et al.**

Serial No. 09/555,473

Filed: May 31, 2000

For: **PHARMACEUTICAL COMPOSITIONS CONTAINING THE  
LONG PENTRAXIN PTX3**

Atty. Ref.: 2801-18

Group: 1644

Examiner: Jamroz

TECH CENTER 1600/2900

NOV 06 2001

RECEIVED

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**AMENDMENT**

Responsive to the Official Action dated October 2, 2001, entry and consideration  
of the following amendments and remarks are requested.

**IN THE CLAIMS**

Amend the claims as follows:

✓  
Cancel claims 9-11, without prejudice.

Add the following claims:

--13. (new) A method of preparing a medicament for the treatment of at least  
one of an infectious disease, an inflammatory disease or a tumour disease, said method  
comprising combining a long pentraxin PTX3 and a pharmaceutically acceptable  
excipient.

14. (new) The method of claim 13, wherein said long pentraxin PTX3 is human  
pentraxin having a sequence of SEQ ID NO: 1.